Bard launches three-minute bladder cancer test
This article was originally published in Clinica
Executive Summary
Bard has launched a three-minute test for bladder cancer. Bard BTA, a latex agglutination and test strip assay, was introduced at the European Urological Winter Forum at Davos, Switzerland. Bard says the kit greatly improves on the noninvasive standard, voided urine cytology (VUC). An unpublished US study is reported to have found BTA to be nine times more sensitive than VUC in detecting Ta (superficial) grade I/II tumours and two and a half times as sensitive in Ta grade III and T1 (invasive) grade II/III tumours. In the case of flat tumours both methods performed equally well. Sensitivity of the new test is 96%.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.